Marico, Dabur shares surge up to 7% post Q1 updates
Dabur India and Marico witness stock price surge following positive Q1 updates. Dabur anticipates single-digit growth with focus on India and international segments. Marico reports uptick in volume growth and strategic collaboration with Kaya. Global brokerage firms maintain ratings and set target prices for both companies.
Shares of FMCG companies India and climbed 4% and 6.5% to their respective day’s highs of Rs 633 and Rs 655 on BSE after the companies posted their Q1FY25 updates.Here are the company-wise Q1 updates:
Dabur India
Dabur, in its filing, stated that the consolidated revenue for the company is expected to register mid to high single-digit growth during Q1 FY25. India's business is expected to record mid-single-digit volume growth.
The quarter saw sequential improvement in demand trends with rural growth picking up. With forecasts of a normal monsoon and continued focus by the government on macroeconomic growth, the company expects improvement to accelerate in the coming months.
In India business, the HPC & Healthcare segment is expected to grow in high-single digits while the international business is expected to post strong growth in constant currency terms.
Following the update, global brokerage firms Morgan Stanley and JP Morgan have maintained an equal-weight and neutral rating respectively on Dabur. Morgan Stanley has set Rs 500 as the target price while JP Morgan has stated Rs 580 as the target price for the stock.
Also read:
Marico
During the quarter, the domestic business posted a modest uptick in underlying volume growth on a sequential basis. Consolidated revenue grew in high single digits while the international business delivered double-digit constant currency growth.
The company expects gross margin to expand on a year-on-year basis owing to a favourable portfolio mix while the operating profit is expected to grow slightly ahead of revenue leading to a marginal inching up of operating margin on a year-on-year basis.
Earlier this month, Maruico also announced that it will collaborate with renowned dermatological solutions provider, , which will likely be an additional growth driver for Marico’s premium personal care-led digital business and further accelerate the portfolio diversification agenda of the India business.
Following Marico’s Q1 business update, global brokerage firms Morgan Stanley and JP Morgan have maintained an equal-weight and overweight rating respectively on the stock. The target price set by Morgan Stanley is Rs 566 while JP Morgan’s target price for Marico is Rs 660.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
Dabur, in its filing, stated that the consolidated revenue for the company is expected to register mid to high single-digit growth during Q1 FY25. India's business is expected to record mid-single-digit volume growth.
The quarter saw sequential improvement in demand trends with rural growth picking up. With forecasts of a normal monsoon and continued focus by the government on macroeconomic growth, the company expects improvement to accelerate in the coming months.
In India business, the HPC & Healthcare segment is expected to grow in high-single digits while the international business is expected to post strong growth in constant currency terms.
Following the update, global brokerage firms Morgan Stanley and JP Morgan have maintained an equal-weight and neutral rating respectively on Dabur. Morgan Stanley has set Rs 500 as the target price while JP Morgan has stated Rs 580 as the target price for the stock.
Also read:
Marico
During the quarter, the domestic business posted a modest uptick in underlying volume growth on a sequential basis. Consolidated revenue grew in high single digits while the international business delivered double-digit constant currency growth.
The company expects gross margin to expand on a year-on-year basis owing to a favourable portfolio mix while the operating profit is expected to grow slightly ahead of revenue leading to a marginal inching up of operating margin on a year-on-year basis.
Earlier this month, Maruico also announced that it will collaborate with renowned dermatological solutions provider, , which will likely be an additional growth driver for Marico’s premium personal care-led digital business and further accelerate the portfolio diversification agenda of the India business.
Following Marico’s Q1 business update, global brokerage firms Morgan Stanley and JP Morgan have maintained an equal-weight and overweight rating respectively on the stock. The target price set by Morgan Stanley is Rs 566 while JP Morgan’s target price for Marico is Rs 660.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
Source: Stocks-Markets-Economic Times
